Nouscom extends Series C round to $82m for cancer vaccine trials
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
What's Your Reaction?
